

CRONOS

G R O U P

April 2019

NASDAQ Ticker: **CRON**

TSX Ticker: **CRON**

Disclaimers & Cautionary Statements


CRONOS GROUP INC.

The information found herein, and any other materials provided by Cronos Group Inc. ("Cronos Group" or the "Company"), are intended solely for discussion purposes and are not intended as, and do not constitute, an offer to sell or a solicitation of an offer to buy any security, and should not be relied upon by you in evaluating the merits of investing in any securities. These materials are not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use is contrary to local law or regulation.

The Company believes the information contained in this document to be reliable but makes no warranty or representation, whether express or implied, in respect of, and assumes no legal liability for, the accuracy, completeness or usefulness of any information disclosed. Any estimates, investment strategies, and views expressed in this document are based upon current market conditions, and/or data and information provided by unaffiliated third parties, and are subject to change without notice. To the extent any information in this document was obtained from third party sources, the Company has not independently verified that information, and there is a risk that the assumptions made and conclusions drawn by the Company based on such representations are not accurate. This document may contain "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements


about strategic plans, including the Company's ability to implement its business development strategy, and its, its joint venture partners' and its joint ventures' future production capacity. Forward-looking information is necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking information involves known and unknown risks, uncertainties and other factors (including the risk factors disclosed under the heading "Risk Factors" in the Company's annual information form dated April 27, 2018, which is available under the Company's SEDAR profile at www.sedar.com) that may cause actual financial results, performance or achievements to be materially different from the future results, performance or achievements expressed or implied by that forward-looking information and the forward-looking information is not a guarantee of future performance. All forward-looking information contained herein is given as of the date hereof and is based upon the opinions and estimates of management and information available to management as at the date hereof. Except as required by law, the Company disclaims any obligation to update or revise any forward-looking information, whether as a result of new information, events or otherwise. Readers are cautioned not to put undue reliance on this forward looking information.

Global Footprint



1) Represents expected capacity. Includes facilities currently under construction.

Strategy





PEACENATURALS

MEDICINAL CANNABIS

Wholly-owned Canadian Licensed Producer; granted the 1st non-incumbent medical cannabis license by Health Canada

CAPACITY

90 acres zoned for cannabis production, extraction, manufacturing and R&D

State-of-the-art 325,000 sq. ft of indoor production facilities and 2,257 sq. ft extraction lab

Onsite 28,000 sq. ft greenhouse serves as both a grow and horticultural technology research facility

IP

Peace Naturals is the hub for research and development – Cronos' Center of Excellence

Bank of over 150 cultivars, including Top 3 In Class cultivars at the 2017 Canadian Cannabis Awards: Raphael, White Widow, and Dancehall

Developed patent pending cannabis extraction technology that maintains aroma profiles of plant extracts, and grow system that minimizes root shock during transplantation and increases plant growth

Active research in plant genetics, grow methodologies, chemical processing, and product formulation



CAPACITY



IP



DISTRIBUTION



BRANDS



PEACENATURALS

MEDICINAL CANNABIS

Wholly-owned Canadian Licensed Producer; granted the 1st non-incumbent medical cannabis license by Health Canada

DISTRIBUTION

Distributes direct to Canadian medical consumers

Good Manufacturing Practices (GMP) requirements

Distributes on an exclusive basis through pharmaceutical manufacturer and supplier, Pohl-Boskamp, to German medical market

Exclusive distribution agreement with pharmaceutical wholesaler, Delfarma, for Polish medical market

BRANDS

Peace Naturals is committed to providing high-quality medicinal cannabis as an alternative to pharmaceutical drugs that have the potential to produce harmful side effects

Peace Naturals™ brand will remain focused on building and shaping the medicinal cannabis market

Tagline: *"Improving the lives of others, one patient at a time"*



CAPACITY



IP



DISTRIBUTION



BRANDS





Wholly-owned Canadian licensed producer based in Okanagan Valley, BC

CAPACITY

13 acres zoned for cannabis production with a 2,500 sq. ft pilot facility for cultivation and genetics trial program; premium genetics sourced from Whistler Medical Marijuana Corporation

Climate and power costs provide advantage over other Canadian jurisdictions; on-site artesian well providing free source of water (200+ gallons per minute capacity)

DISTRIBUTION

Recreational brands for the Canadian adult-use market distributed to Ontario, British Columbia, Nova Scotia and Prince Edward Island

BRANDS

Launched Original BC (OGBC) as a platform for recreational brands, focused on the mainstream and premium markets

Leveraging the reputation of the Okanagan Valley in British Columbia, known for producing some of Canada's best cannabis

Focus on a small-batch and crafted look and feel, perfected by our team of experts, never settling for shortcuts



CAPACITY



DISTRIBUTION



BRANDS



Recreational brands for the Canadian adult-use market

COVE™

Positioned as a premium recreational brand

Focused on every detail of the process, COVE™ products are non-irradiated and hand-trimmed using only the best flowers from each harvest

By avoiding shortcuts like harsh refining processes and using Cronos Group's patent-pending extraction technology, COVE™ is able to maintain the natural balance of the plant across all of the brand's terpene-rich cannabis extracts

The goal of this premium brand is to make each experience a discovery for COVE™ consumers

More information on COVE™ can be found at www.covecannabis.ca

SPINACH™

Positioned as a mainstream recreational brand

The brand is geared towards wide range of consumers that don't take life too seriously and are looking for entertaining, fun ways to enhance activities

A fun, lighthearted and playful brand, Spinach™ is focused on offering Farm-To-Bowl™ products that bring friends together and make experiences more enjoyable

More information on how to GET YOUR GREENS™ can be found at www.spinachcannabis.com



CAPACITY



IP



DISTRIBUTION



BRANDS



GINKGO BIOWORKS

THE ORGANISM COMPANY



CAPACITY



IP

Landmark Partnership to Produce Pure Cultured Cannabinoids at Scale

CAPACITY

Cronos Group can leverage existing fermentation infrastructure (e.g. breweries or pharmaceutical CMOs) to produce large volumes of the target cannabinoids from the custom yeast strains without incurring heavy CapEx to build new cultivation and extraction facilities

IP

Ginkgo Bioworks has developed a platform to create custom microorganisms for biosynthesizing products at commercial scale and high purity for sophisticated clients in diverse industries

Using this platform, Cronos Group expects to obtain custom yeast strains capable of producing cannabinoids, including rare cannabinoids, at a fraction of the cost of currently available methods (under US\$1,000/kg)

Cronos Group will have an exclusive, royalty-free license to key technology for the production and commercialization of the 8 major target cannabinoids





CRONOS

I S R A E L

Strategic JV with Kibbutz Gan Shmuel, a commercial kibbutz and food company
Obtained nursery, cultivation and distribution initial licenses

CAPACITY

Ideal climate enables production of high quality medical cannabis in a 45,000 sq. ft greenhouse

Over 1,000 agriculturally skilled Kibbutz members live on site and existing infrastructure available to support operations

Situated on mixed-use agricultural/industrial land with ability to expand up to 100,000 kg annually

IP

Strategically located in Israel, the leader in research and development on medical cannabis

Research with Hebrew University on nano emulsion technology

DISTRIBUTION

Gan Shmuel currently exports to 35 countries across Europe and Asia, through Gan Shmuel Foods Ltd., a publicly traded food company listed on the Tel Aviv Exchange



CAPACITY



IP



DISTRIBUTION



CRONOS

A U S T R A L I A

50/50 JV with Australian-based New Southern Capital
Received medicinal cultivation, research and manufacture licenses

CAPACITY

The state-of-the-art facility will be located on 120 acre production campus in regional Victoria

The initially planned, purpose-built 20,000 sq. ft indoor facility has an expected annual production capacity of 2,000 kg*

The facility is expected to be designed to meet Good Production Practices and Good Manufacturing Practices (GMP) requirements

IP

Cronos Australia holds a research license, and is expected to develop and commercialize valuable new IP, including new cultivars

DISTRIBUTION

Cronos Australia is expected to be the hub for distribution through Australia, New Zealand, and South East Asia

Cronos Australia has applied for both import and export licenses



CAPACITY



IP



DISTRIBUTION



CRONOS

G R O W C O

Strategic JV with Bert Mucci, owner and operator of Mucci Farms

CAPACITY

Partnered with one of the most sophisticated greenhouse growers in North America

Located in Leamington/Kingsville region of Ontario, home to the largest concentration of greenhouses in North America and commonly referred to as the "Sun Parlour"

Cronos GrowCo plans to develop an approximately 850,000 sq. ft custom-built greenhouse on 100 acres of land owned by Cronos GrowCo

The facility is expected to produce approximately 70,000 kg per annum; and is designed to meet GAP and GMP requirements and standards for cultivation, extraction and manufacturing activities

Capacity can be used for both medical and recreational markets and offers access to debt financing

DISTRIBUTION

Cura Cannabis Solutions, one of the largest cannabis companies in the world, has entered into one of the largest supply agreements in the cannabis industry with Cronos GrowCo

Cura has signed a 5 year take-or-pay supply agreement to purchase >20,000 kg of cannabis per annum from Cronos GrowCo

Cronos GrowCo will be a source of capacity as value-added products are permitted in the Canadian recreational market, expected October 2019



CAPACITY



DISTRIBUTION



NatuEra

50/50 joint venture between Cronos Group and Agriodea (AGI), creating NatuEra, the cannabis industry's first CMO in LATAM

CAPACITY

NatuEra plans to develop its initial cultivation and manufacturing operations with a custom-built facility on 207 acres of available land located in Cundinamarca, Colombia

The natural environment and climate conditions of this region are particularly well suited for the cultivation of cannabis, Colombia is a global leader in tropical agricultural products for export and is poised to play a pivotal role as the cannabis industry expands globally and new markets continue to open

The state-of-the-art facility is expected to be designed to meet GAP and GMP requirements and standards for cultivation, extraction, manufacturing and export activities

AGI's experience includes the acquisition, re-structuring and management of Dole Food's Fresh-Cut Flower Division, one of the world's largest flower growing operations, with a greenhouse cultivation footprint of over 1,020 acres

DISTRIBUTION

NatuEra is expected to be the hub and platform through which Cronos Group will access the Latin America market

As a CMO, NatuEra intends to allow the growing number of cannabis brands worldwide to outsource their development, cultivation, and/or manufacturing activities



CAPACITY



DISTRIBUTION



MedMen™

50/50 strategic branding partnership with MedMen

DISTRIBUTION

MedMen Canada will open stores across Canada in provinces allowing for private retail, leveraging Cronos' reach and MedMen's retail expertise

Targeted, high foot-traffic, metropolitan locations attracting premium consumers

Retail distribution will inform a consumer who is an occasion-based purchaser or still sampling to understand the available products and brands

BRANDS

MedMen™ is one of the most recognized cannabis brands in the world, known as "the Apple Store of cannabis"

MedMen Canada will launch branded MedMen™ products

Retail stores will hold influence as branding and advertising will be restricted

Collect POS data to understand consumer habits and inform product development

MedMen Canada holds the exclusive license to the MedMen™ brand in Canada



DISTRIBUTION



BRANDS

Global Distribution



DISTRIBUTION

GERMANY

Exclusive 5 year supply agreement with Pohl-Boskamp, an international pharmaceutical manufacturer and supplier founded in 1835

Pohl distributes products to 10,550 German pharmacies

Large shortage of medical cannabis in Germany

German parliament implemented health insurance coverage for patients

Peace Naturals exports 15 different monographs

POHL BOSKAMP




POLAND

Exclusive 5 year supply agreement with Delfarma, an international pharmaceutical wholesaler founded in 2004



Delfarma distributes products to 5,000 pharmacies and 200 hospitals, a distribution network that reaches ~40% of the Polish domestic market

First LP to receive distribution agreement in Poland

Peace Naturals is currently registering monographs



Appendix



Capacity




Facility	Location	Grow Type	Square Footage	Estimated Annual Capacity (kg)
Existing Capacity⁽¹⁾				
Peace Naturals - Buildings 1,2,3, 4 ⁽²⁾	Stayner, ON, Canada	Indoor	325,000	38,500
Peace Naturals - Greenhouse	Stayner, ON, Canada	Greenhouse	28,000	1,500
OGBC	Armstrong, BC, Canada	Indoor	2,500	150
Existing Capacity			355,500	40,150
Capacity in Progress				
Cronos Israel - Phase I ⁽³⁾	Hadera, Israel	Greenhouse	45,000	5,000
Cronos Australia - Phase I ⁽⁴⁾	Melbourne, VIC, Australia	Indoor	20,000	2,000
Cronos GrowCo ⁽⁵⁾	Kingsville, ON, Canada	Greenhouse	850,000	70,000
NatuEra ⁽⁶⁾	Cundinamarca, Colombia	Greenhouse	*	*
Capacity in Progress			915,000	77,000
Pro Forma			1,270,500	117,150

1) Existing capacity is defined as facilities where construction is substantially complete, regulatory approvals required to commence operations have been received and cannabis cultivation has commenced.
 2) Building 4 is expected to become operational in phases. Currently, Building 4 engages in the cultivation of cannabis, with Peace Naturals having received an amendment to its license to cultivate cannabis in Building 4 on August 31, 2018. It is expected that Building 4 will also engage in processing, extraction, finishing and packaging and shipping activities following receipt of the applicable regulatory approvals or amendments to the Peace Naturals license. While construction of Building 4 is complete, the GMP-grade and industrial-grade kitchen and certain additional cultivation and processing areas are in the process of being equipped and made operational in phases. The research and development areas and certain laboratory areas in Building 4 are in final design phases.
 3) Cronos Group holds a 70% interest in the cultivation company, and a 90% interest in each of the manufacturing, distribution and pharmacies companies of Cronos Israel (as defined herein).
 4) Cronos Group owns a 50% equity interest in Cronos Australia
 5) Cronos Group owns a 50% equity interest in Cronos GrowCo
 6) Cronos Group owns a 50% equity interest in NatuEra. NatuEra is in the design phase and initial planned capacity is still being finalized.

Financial / Snapshot¹


STOCK INFORMATION:	
LISTED MARKETS	Nasdaq Global Market Toronto Stock Exchange
TICKER SYMBOL	CRON
52 WEEK LOW/HIGH	C\$6.57 - C\$32.95 ²
AVG. DAILY VOLUME (90 DAY)	14,500,000 ³
COMMON SHARES OUTSTANDING	325M: 178M + 146M Altria



1) All information is as of March 26, 2019 or for quarter end December 31, 2018, as applicable
 2) 52 week low/high stock price and Market Cap quoted in CAD as of April 1, 2019
 3) 90 Day Average Daily Volume on Nasdaq as of April 1, 2019

Ginkgo Partnership Overview

- Ginkgo Bioworks to design microorganisms which can produce desired “target cannabinoids” at an industrial scale
- 8 target cannabinoids to be produced by yeast via industrial fermentation
- Target production yields at a fraction of the cost of traditional cannabinoids production in plants: **< \$1,000 USD per KG**
- Cronos Group will have the exclusive right to use and commercialize the key patented intellectual property related to the production of the target cannabinoids perpetually and globally



CRONOS Management Team



Michael Gorenstein

President, CEO & Chairman

Former Partner at Alphabet Ventures LLC

M&A at Sullivan & Cromwell LLP

J.D. from University of Pennsylvania Law School

Bachelor of Science in Business from the Kelley School of Business at Indiana University



David Hsu

Chief Operating Officer

Financial and operational restructuring expertise Former VP at Deloitte CRG

Bachelor of Science in Business Management from Babson College



William Hilson

Chief Financial Officer

15+ years as regional CFO for Serono & Merck

MSc in Clinical Biochemistry from the University of Toronto

Honours Bachelor of Genetics from the University of Western Ontario



Xiuming Shum


General Counsel

Corporate Attorney at BNP Paribas

M&A at Sullivan & Cromwell LLP

J.D. from Columbia Law School

Bachelor of Laws from University College London



Eric Klein

Marketing

10+ years in brand management at PepsiCo, Chobani, and Kraft

MBA from University of Chicago Booth School of Business

Bachelor of Business Administration from Emory University



Kevin Gifford

VP, Finance & Corporate Development

15+ years in investment roles in PE and the Americas Special Situations Group at Goldman Sachs & Co.

MBA. from the University of Michigan

Bachelor of Science in Economics from The Wharton School at the University of Pennsylvania



Jeff Jacobson

Head of Business Development & Regulatory Affairs

Government relations and regulatory expert

Founder of a Toronto based marketing agency

Founding member of Peace Naturals



Dr. Lasse Schulze

Head of Horticulture

10+ years international experience in the Horticultural Industry

Consultant for the Gates Foundation

Ph.D. in Plant Physiology and Toxicology from the University of Toronto



Anna Shlimak

Investor Relations & Communications

10+ years in investor relations for hedge fund and public company at the New York Stock Exchange

MBA from Columbia Business School

Bachelor of Science in Economics from The Wharton School at the University of Pennsylvania

A scenic landscape at sunset. A dirt road with tire tracks runs through a green field, bordered by a wooden fence. In the background, there are large, dark trees and a bright sun setting behind them, creating a warm, golden glow. The sky is filled with soft, orange and yellow clouds.

Thank You

Contact Information

720 King Street West, Suite 320

Toronto, Ontario M5V 2T3

Office: (416) 504-0004

Investor.Relations@TheCronosGroup.com

V-0018

NASDAQ Ticker: CRON

TSX Ticker: CRON